Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company announced its brain cancer imaging drug, Pixclara, has won approval from the US FDA—making it the first FET-PET imaging drug cleared for use in glioma and expanding Telix’s precision medicine portfolio.

What did Telix Pharmaceuticals report?

• FDA approved Pixclara® (floretyrosine F 18), for imaging gliomas (brain cancer) in adult and paediatric patients
• Pixclara is the first FDA-approved FET-PET imaging drug for glioma
• Pixclara’s approval addresses a significant unmet need in US brain cancer diagnostics
• Product expansion reinforces Telix’s position in precision diagnostics and targeted radiopharmaceutical “theranostics”

What else do investors need to know?

Pixclara is the only FDA-approved radiopharmaceutical imaging drug specifically for glioma, a difficult-to-treat brain cancer representing around 24,000 new cases annually in the US. The new drug is indicated for adults and children as young as one month old and is expected to support better treatment decision-making for both clinicians and patients.

The approval also makes Pixclara eligible for widespread clinical use. FET-PET imaging has been recommended in various international guidelines, but until now, there was no FDA-approved product available in the United States. Telix already has other FDA-approved imaging offerings and is working on advancing late-stage therapies across multiple cancers.

What did Telix Pharmaceuticals management say?

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said:

FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients.

What’s next for Telix Pharmaceuticals?

Telix says Pixclara is already the subject of a Phase 3 trial for diagnosis in additional brain conditions, with potential expansion to brain metastases. The company continues to leverage its global diagnostics platform and late-stage radiopharmaceutical pipeline to target market leadership in both imaging and treatment for several high-need cancers.

Telix’s broader pipeline includes late-stage assets in prostate, kidney, and glioblastoma cancers, with a focus on bringing further precision medicine products to both existing and new markets worldwide.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have risen 12%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has declined 1% over the same period.

View Original Announcement

The post Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug appeared first on The Motley Fool Australia.

More reading

• Forget CSL shares. 3 ASX healthcare stocks with bigger upside
• CSL led the ASX healthcare shares rebound. Can it continue?
• 4 high conviction ASX stock picks from Canaccord Genuity
• Telix shares are up 98%: Is there more upside to come?
• Telix shares are tumbling. Is the stock finally at fair value?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.